A Pragmatic Study of MRD-Guided Maintenance for Multiple Myeloma in Latin America
Applicability of MRD to Tailored Maintenance in Multiple Myeloma: A Pragmatic Prospective Multicenter Study in Latin America
This prospective, pragmatic, multicenter study aims to evaluate the clinical and quality-of-life outcomes of discontinuing maintenance therapy in newly diagnosed MM patients with sustained MRD negativity for two years. By implementing a structured active surveillance strategy with serial MRD and QoL assessments, this study seeks to determine whether treatment-free intervals can be safely achieved without compromising survival outcomes, while improving patient well-being and reducing financial burden.
If successful, this study will provide foundational evidence to support MRD-guided, individualized maintenance strategies in MM and will serve as a platform for future interventional trials in Latin America.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Multiple myeloma is a blood cancer that can require long-term maintenance treatment, even after a very good response to initial therapy. Although maintenance treatment can help control the disease, continuing it for many years may cause side effects, affect quality of life, and create financial burdens. Measurable residual disease (MRD) testing can detect very small amounts of myeloma cells that may remain after treatment.
This prospective, multicenter study in Latin America will evaluate a strategy of stopping maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved a complete or stringent complete response and have remained MRD-negative for at least two consecutive years while receiving maintenance therapy.
After maintenance therapy is discontinued, participants will be followed for 24 months through clinical assessments, MRD testing, and quality-of-life questionnaires every six months. Maintenance therapy will be restarted if MRD reappears or if clinical or biochemical criteria for disease relapse are met, according to the study protocol.
The main objective is to evaluate whether this strategy can be implemented safely and to measure the occurrence of MRD reappearance, disease relapse, or death within 24 months. Additional objectives include evaluating progression-free survival, overall survival, quality of life, time until maintenance therapy is restarted, and the feasibility of this approach across Latin American centers.
The study aims to generate evidence to help guide individualized maintenance treatment decisions for selected patients with multiple myeloma.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Yadith Karina Lopez Garcia, MD
- Telefonní číslo: +52 81 8675 6718
- E-mail: yadith.lopezgrc@uanl.edu.mx
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age ≥18 years at the time of enrollment.
- Diagnosis of newly diagnosed multiple myeloma according to International Myeloma Working Group (IMWG) criteria.
- Achievement of complete response (CR) or stringent complete response (sCR) following first-line therapy, with or without autologous hematopoietic cell transplantation (auto-HCT).
- Receipt of maintenance therapy for a minimum of 12 months prior to screening.
- Sustained measurable residual disease (MRD) negativity documented by next-generation flow cytometry (NGF assay EuroFlow-based or equivalent): MRD negativity confirmed on at least two consecutive bone marrow assessments, separated by a minimum of 12 months, with assessments performed during ongoing maintenance therapy.
- Negative functional imaging prior to maintenance discontinuation, defined as no evidence of metabolically active focal lesions on PET/CT, performed during screening.
- Absence of extramedullary disease at the time of study entry.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Ability to comply with study procedures, including serial MRD and quality-of-life assessments.
- Provision of written informed consent prior to any study-specific procedures.
Exclusion Criteria:
- Evidence of MRD positivity by NGF at any assessment during screening.
- PET/CT-positive lesions suggestive of active myeloma at screening.
- Biochemical or clinical relapse at the time of screening, as defined by IMWG criteria.
- Prior progression while receiving maintenance therapy.
- Any uncontrolled medical condition or comorbidity that, in the investigator's judgment, would compromise patient safety or protocol compliance.
- Inability or unwillingness to adhere to protocol-defined follow-up and surveillance procedures.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: MRD-Guided Maintenance Discontinuation and Active Surveillance
Eligible participants will discontinue maintenance therapy after meeting the protocol-defined criteria, including sustained measurable residual disease (MRD) negativity for at least two consecutive years and no evidence of active disease on PET/CT. Participants will undergo active surveillance for 24 months, with clinical assessments, MRD testing, and health-related quality-of-life evaluations every six months. If MRD reappears or clinical or biochemical disease relapse criteria are met, maintenance therapy will be reinitiated according to the study protocol. All participants will receive the same intervention strategy, as this is a single-arm study. |
The intervention consists of discontinuing maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved complete response or stringent complete response and sustained measurable residual disease (MRD) negativity for at least two consecutive years during maintenance therapy, with no evidence of active disease on PET/CT. Following discontinuation, participants will undergo active surveillance for 24 months, with clinical assessments, bone marrow MRD testing, and health-related quality-of-life evaluations every six months. MRD will be assessed using next-generation flow cytometry. Maintenance therapy will be reinitiated if MRD reappears or if clinical or biochemical disease relapse criteria are met, according to the study protocol. The strategy is evaluated prospectively in a single-arm, multicenter study across Latin America. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Strategy Failure Rate at 24 Months Following MRD-Guided Maintenance Discontinuation
Časové okno: From maintenance discontinuation (baseline) through 24 months.
|
Strategy failure is defined as the first occurrence of any of the following events after maintenance discontinuation: (1) measurable residual disease (MRD) resurgence, defined as conversion from sustained MRD negativity to MRD positivity detected by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5); (2) clinical or biochemical relapse/progression according to IMWG criteria; or (3) death from any cause. The outcome will be measured as the proportion of participants experiencing at least one strategy failure event. |
From maintenance discontinuation (baseline) through 24 months.
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Measurable Residual Disease-Free Survival (MRD-FS)
Časové okno: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to the first occurrence of MRD resurgence or death from any cause. MRD will be assessed using next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). MRD-FS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Treatment-Free Survival (TFS)
Časové okno: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to re-initiation of maintenance therapy or death from any cause, whichever occurs first. TFS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Progression-Free Survival (PFS)
Časové okno: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to documented clinical or biochemical disease progression according to IMWG criteria or death from any cause, whichever occurs first. PFS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Overall Survival (OS)
Časové okno: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to death from any cause. Overall survival will be estimated using the Kaplan-Meier method, with survival probabilities reported at 12 and 24 months. |
From maintenance discontinuation through 24 months.
|
|
Measurable Residual Disease (MRD) Resurgence Rate
Časové okno: At months 6, 12, 18, and 24 after maintenance discontinuation.
|
Proportion of participants who convert from sustained MRD negativity to MRD positivity during follow-up, assessed by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). |
At months 6, 12, 18, and 24 after maintenance discontinuation.
|
|
Time to Maintenance Therapy Re-initiation
Časové okno: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to the re-initiation of maintenance therapy, regardless of whether treatment is restarted due to MRD resurgence, clinical or biochemical relapse, or investigator discretion. |
From maintenance discontinuation through 24 months.
|
|
Change From Baseline in Health-Related Quality of Life Assessed by EORTC QLQ-C30
Časové okno: Baseline and months 6, 12, 18, and 24.
|
Changes in health-related quality of life will be assessed using the EORTC QLQ-C30 questionnaire. |
Baseline and months 6, 12, 18, and 24.
|
|
Change From Baseline in Multiple Myeloma-Specific Quality of Life Assessed by EORTC QLQ-MY20
Časové okno: Baseline and months 6, 12, 18, and 24.
|
Changes in multiple myeloma-specific health-related quality of life will be assessed using the EORTC QLQ-MY20 questionnaire. |
Baseline and months 6, 12, 18, and 24.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Cévní onemocnění
- Kardiovaskulární choroby
- Novotvary
- Onemocnění imunitního systému
- Novotvary podle histologického typu
- Hematologická onemocnění
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Novotvary, plazmatické buňky
- Hemostatické poruchy
- Paraproteinémie
- Poruchy krevních bílkovin
- Hemoragické poruchy
- Hemická a lymfatická onemocnění
- Mnohočetný myelom
- Správa zdravotnických služeb
- Kvalita zdravotní péče
- Posouzení výsledku, zdravotní péče
- Výsledek a posouzení procesů, zdravotní péče
- Ostražité čekání
Další identifikační čísla studie
Další identifikační čísla studie
- HE26-00024
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .